Back to Search
Start Over
Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo.
- Source :
-
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 1997 Jul; Vol. 44 (5), pp. 273-81. - Publication Year :
- 1997
-
Abstract
- Interleukin(IL)-1 differs from most other cytokines in its lack of a signal sequence. This results in intracellular retention of the immature proform. The release of IL-1 has been shown to be restricted predominantly to activated monocytes and macrophages and to be associated with apoptosis of the producer cell. These features have limited the investigation of IL-1 in early immune responses. In order to study the biological effects of local IL-1 beta release during an antitumour immune response, we used B16 mouse melanoma cells transduced with mature human IL-1 beta cDNA constructs. To obtain a released form of human IL-1 beta (ssIL-1 beta), the signal sequence from the related IL-1 receptor antagonist was ligated to the cDNA that encoded the mature form of IL-1 beta. When cells of the poorly immunogenic B16 melanoma cell line were transduced with IL-1 beta by retroviral infection, high levels of the protein were detected intracellularly, whereas cells transduced with IL-1 beta containing the signal sequence secreted most of their protein. The in vitro growth of the melanoma cells was unaffected by the IL-1 beta or ssIL-1 beta gene transfer. In contrast, the in vivo subcutaneous tumour growth of the ssIL-1 beta-transduced B16 cells in syngeneic C57BL/6 mice was significantly reduced compared with the IL-1 beta- and the mock-transduced controls. Immunohistochemical analysis revealed the infiltration of macrophages to be strong in B16/ssIL-1 beta, moderate in B16/IL-1 beta and minimal in control tumours. Furthermore, a moderate infiltration of CD4+ cells and of scattered dendritic cells was detected in B16/ssIL-1 beta tumours whereas very few or no CD4+ cells and dendritic cells were seen in the B16/IL-1 beta or control tumours. Following in vivo growth, all the tumours upregulated ICAM-1 on their cell surfaces. However, the percentage of ICAM-1-expressing cells was two- to four-fold higher in B16/ssIL-1 beta tumours compared to the control. The data suggest that IL-1 beta acts in vivo, either directly or indirectly, as a chemotactic factor for monocytes, T helper cells and dendritic cells. This supports IL-1 beta having a regulatory effect on tumour growth when locally released in the tumour area.
- Subjects :
- Animals
Flow Cytometry
Genetic Engineering
Humans
Immunohistochemistry
Interleukin-1 genetics
Melanoma, Experimental genetics
Melanoma, Experimental pathology
Mice
Mice, Inbred C57BL
Protein Sorting Signals genetics
Survival Analysis
Dendritic Cells immunology
Interleukin-1 metabolism
Macrophages immunology
Melanoma, Experimental immunology
T-Lymphocyte Subsets immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0340-7004
- Volume :
- 44
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cancer immunology, immunotherapy : CII
- Publication Type :
- Academic Journal
- Accession number :
- 9247562
- Full Text :
- https://doi.org/10.1007/s002620050383